Pre-order Enquiry
Request Free Sample
Healthcare
Aerospace & Defence
Agriculture
Automations
Chemicals & Advanced Materials
Food & Beverages
Information & Communication Technology
Oil & Gas
Power & Energy
According to the latest research, the global Ketamine Treatment market size was valued at USD 298.39 million in 2022 and is expected to expand at a CAGR of 31.52% during the forecast period, reaching USD 1544.21 million by 2028.
Ketamine is a powerful psychedelic substance with strong dissociative effects used as a general anesthetic in medicine. It has a long history as a party-drug, but more recently ketamine has been found to have therapeutic benefits, specifically when treating treatment-resistant depression, PTSD, and addiction. Ketamine, which was initially used as an anesthetic, is now used in treating depression, anxiety, and post-traumatic stress disorder (PTSD). Ketamine participates in the treatment process in the form of infusions and nasal sprays.
Bring volatility in the short term
COVID-19 has just broken out, and major economies have responded positively by adopting policies such as suspension of work and production, and home isolation, which have had some negative impacts on Ketamine production and ketamine treatment. In the short term, Ketamine Treatment will be suppressed in the short term due to home isolation to prevent and control the epidemic.
Long-term positive impact
During COVID-19, people stay in isolation at home, socializing is blocked, and patients with depression continue to increase. The number of American adults reporting symptoms of stress, anxiety, and depression during the pandemic has increased significantly. The demand for treatment for depression is increasing. At the same time, treatment is a rigid demand, and the demand for Ketamine, which acts as an anesthetic treatment or an analgesic, remains strong. With the gradual improvement of the epidemic, the treatment of other diseases such as surgery has returned to normal, people's demand for hospitals has recovered, and the demand for Ketamine Treatment is also increasing.
There are side effects
Ketamine taken under medical supervision is considered a relatively safe drug. Ketamine is not considered to be a physical addiction, but it may still cause psychological dependence. Patients with high blood pressure, thyroid disease, alcoholism, and aneurysms should use ketamine with caution, because ketamine can increase blood pressure. It has been found that frequent use of high doses can cause neurodegeneration, and frequent use of high doses of ketamine can cause liver and urinary system toxicity. Ketamine can cause increased blood pressure and intracranial pressure, or increased brain pressure. It can also cause loss of appetite, stomach upset, and vomiting. A certain degree of side effects, for certain people, such as coronary artery disease, thyroid disease, chronic alcohol addiction, etc., especially people over 65 years old, ketamine treatment will be limited. Ketamine is also not recommended for pediatric patients younger than 3 months. The existence of side effects has a certain degree of negative impact on the development of the industry.
Prosperity of clinical experimental research
Ketamine's recent breakthrough has cast a huge spotlight on all of the possible medical benefits of the substance. Here are a few current clinical trials: Emergency Ketamine Treatment of Suicidal Ideation; Ketamine Treatment for Pediatric-Refractory Obsessive-Compulsive Disorder (OCD); Open Label Ketamine Treatment for Major Depressive Disorder in Veterans; Ketamine Treatment Effects on Synaptic Plasticity in Depression; Investigation of Antidepressant Efficacy of Oral Ketamine Treatment, etc. With the development of clinical research, the emphasis on Ketamine Treatment will continue to increase, which will also promote the high-level development of the Ketamine Treatment market and bring development opportunities.
Region Overview:
In 2022, the share of the Ketamine Treatment market in United States stood at 62.24%.
Company Overview:
Numinus is an integrated mental health company creating an ecosystem of health solutions to research, develop, and deliver safe, evidence-based, accessible psychedelic-assisted psychotherapy.
Numinus Bioscience is a Health Canada-licensed lab for psychedelic substance research, developing IP while offering analytics services for revenue generation.Numinus Health supports practitioners in delivering best-in-class treatments by offering centralized, Numinus-owned training, facilities and other operational resources for effective care delivery and healthcare impact.
Mindbloom, Inc. is a platform serving independently owned and operated affiliated psychiatric healthcare facilities and in no way owns, directs or controls the mental health care clinicians who provide care. Mindbloom is clinicians, technologists, patients, and researchers partnering to increase access to science-backed mental health and wellbeing treatments, starting with guided ketamine therapy for depression and anxiety.
Numinus Wellness is one of the major players operating in the Ketamine Treatment market, holding a share of 3.93% in 2023.
Segmentation Overview:
As for product types, the Infusions segment held the largest market share in 2022.
Application Overview:
The market's largest segment by application is the segment Depression, with a market share of 61.30% in 2022.
This report elaborates on the market size, market characteristics, and market growth of the Ketamine Treatment industry between the year 2018 to 2028, and breaks down according to the product type, downstream application, and consumption area of Ketamine Treatment. The report also introduces players in the industry from the perspective of the value chain and looks into the leading companies.
Key Points this Global Ketamine Treatment Market Report Include:
Market Size Estimates: Ketamine Treatment market size estimation in terms of revenue and sales from 2018-2028
Market Dynamic and Trends: Ketamine Treatment market drivers, restraints, opportunities, and challenges
Macro-economy and Regional Conflict: Influence of global inflation and Russia & Ukraine War on the Ketamine Treatment market
Segment Market Analysis: Ketamine Treatment market revenue and sales by type and by application from 2018-2028
Regional Market Analysis: Ketamine Treatment market situations and prospects in major and top regions and countries
Ketamine Treatment Market
Ketamine Treatment Industry Chain: Ketamine Treatment market raw materials & suppliers, manufacturing process, distributors by region, downstream customers
Ketamine Treatment Industry News, Policies by regions
Ketamine Treatment Industry Porters Five Forces Analysis
Key players in the global Ketamine Treatment market are covered in Chapter 2:
Field Trip Health
Mindbloom
Nue Life Health
Save Minds
Nushama
Numinus Wellness
Ember Health
Interpersonal Psychiatry
Klarisana
Journey Clinical
Better U
In Chapter 6 and Chapter 9, on the basis of types, the Ketamine Treatment market from 2018 to 2028 is primarily split into:
Infusions
Nasal Spray
Tablets
In Chapter 7 and Chapter 10, on the basis of applications, the Ketamine Treatment market from 2018 to 2028 covers:
Depression
Anesthesia
Pain
Other
Geographically, the detailed analysis of consumption, revenue, market share and growth rate of the following regions from 2018 to 2028 are covered in Chapter 8 and Chapter 11:
United States
Europe
China
Japan
India
Southeast Asia
Latin America
Middle East and Africa
Others
In summary, this report relies on sources from both primary and secondary, combines comprehensive quantitative analysis with detailed qualitative analysis, and pictures the market from a macro overview to micro granular segment aspects. Whatever your role in this industry value chain is, you should benefit from this report with no doubt.
Chapter Outline
This report consists of 12 chapters. Below is a brief guideline to help you quickly grasp the main contents of each chapter:
Chapter 1 first introduces the product overview, market scope, product classification, application, and regional division, and then summarizes the global Ketamine Treatment market size in terms of revenue, sales volume, and average price.
Chapter 2 analyzes the main companies in the Ketamine Treatment industry, including their main businesses, products/services, sales, prices, revenue, gross profit margin, and the latest developments/updates.
Chapter 3 is an analysis of the competitive environment of Ketamine Treatment market participants. This mainly includes the revenue, sales, market share, and average price of the top players, along with the market concentration ratio in 2022 and the players' M&A and expansion in recent years.
Chapter 4 is an analysis of the Ketamine Treatment industrial chain, including raw material analysis, manufacturing cost structure, distributors, and major downstream buyers.
Chapter 5 focuses on Ketamine Treatment market dynamics and marketing strategy analysis, which include opportunities, challenges, industry development trends under inflation, industry news and policies analyzed by region, Porter's Five Forces analysis, as well as direct and indirect marketing, and the development trends of marketing channels.
Chapters 6-8 have segmented the Ketamine Treatment market by type, application, and region, with a focus on sales and value from 2018 to 2023 from both vertical and horizontal perspectives.
Chapters 9-11 provide detailed Ketamine Treatment market forecast data for 2023-2028, broken down by type and application, region, and major countries to help understand future growth trends.
Chapter 12 concludes with an explanation of the data sources and research methods. Verify and analyze through preliminary research to obtain final quantitative and qualitative data.
2022
Ketamine is a powerful psychedelic substance with strong dissociative effects used as a general anesthetic in medicine. It has a long history as a party-drug, but more recently ketamine has been found to have therapeutic benefits, specifically when treating treatment-resistant depression, PTSD, and addiction. Ketamine, which was initially used as an anesthetic, is now used in treating depression, anxiety, and post-traumatic stress disorder (PTSD). Ketamine participates in the treatment process in the form of infusions and nasal sprays.
Bring volatility in the short term
COVID-19 has just broken out, and major economies have responded positively by adopting policies such as suspension of work and production, and home isolation, which have had some negative impacts on Ketamine production and ketamine treatment. In the short term, Ketamine Treatment will be suppressed in the short term due to home isolation to prevent and control the epidemic.
Long-term positive impact
During COVID-19, people stay in isolation at home, socializing is blocked, and patients with depression continue to increase. The number of American adults reporting symptoms of stress, anxiety, and depression during the pandemic has increased significantly. The demand for treatment for depression is increasing. At the same time, treatment is a rigid demand, and the demand for Ketamine, which acts as an anesthetic treatment or an analgesic, remains strong. With the gradual improvement of the epidemic, the treatment of other diseases such as surgery has returned to normal, people's demand for hospitals has recovered, and the demand for Ketamine Treatment is also increasing.
There are side effects
Ketamine taken under medical supervision is considered a relatively safe drug. Ketamine is not considered to be a physical addiction, but it may still cause psychological dependence. Patients with high blood pressure, thyroid disease, alcoholism, and aneurysms should use ketamine with caution, because ketamine can increase blood pressure. It has been found that frequent use of high doses can cause neurodegeneration, and frequent use of high doses of ketamine can cause liver and urinary system toxicity. Ketamine can cause increased blood pressure and intracranial pressure, or increased brain pressure. It can also cause loss of appetite, stomach upset, and vomiting. A certain degree of side effects, for certain people, such as coronary artery disease, thyroid disease, chronic alcohol addiction, etc., especially people over 65 years old, ketamine treatment will be limited. Ketamine is also not recommended for pediatric patients younger than 3 months. The existence of side effects has a certain degree of negative impact on the development of the industry.
Prosperity of clinical experimental research
Ketamine's recent breakthrough has cast a huge spotlight on all of the possible medical benefits of the substance. Here are a few current clinical trials: Emergency Ketamine Treatment of Suicidal Ideation; Ketamine Treatment for Pediatric-Refractory Obsessive-Compulsive Disorder (OCD); Open Label Ketamine Treatment for Major Depressive Disorder in Veterans; Ketamine Treatment Effects on Synaptic Plasticity in Depression; Investigation of Antidepressant Efficacy of Oral Ketamine Treatment, etc. With the development of clinical research, the emphasis on Ketamine Treatment will continue to increase, which will also promote the high-level development of the Ketamine Treatment market and bring development opportunities.
Region Overview:
In 2022, the share of the Ketamine Treatment market in United States stood at 62.24%.
Company Overview:
Numinus is an integrated mental health company creating an ecosystem of health solutions to research, develop, and deliver safe, evidence-based, accessible psychedelic-assisted psychotherapy.
Numinus Bioscience is a Health Canada-licensed lab for psychedelic substance research, developing IP while offering analytics services for revenue generation.Numinus Health supports practitioners in delivering best-in-class treatments by offering centralized, Numinus-owned training, facilities and other operational resources for effective care delivery and healthcare impact.
Mindbloom, Inc. is a platform serving independently owned and operated affiliated psychiatric healthcare facilities and in no way owns, directs or controls the mental health care clinicians who provide care. Mindbloom is clinicians, technologists, patients, and researchers partnering to increase access to science-backed mental health and wellbeing treatments, starting with guided ketamine therapy for depression and anxiety.
Numinus Wellness is one of the major players operating in the Ketamine Treatment market, holding a share of 3.93% in 2023.
Segmentation Overview:
As for product types, the Infusions segment held the largest market share in 2022.
Application Overview:
The market's largest segment by application is the segment Depression, with a market share of 61.30% in 2022.
This report elaborates on the market size, market characteristics, and market growth of the Ketamine Treatment industry between the year 2018 to 2028, and breaks down according to the product type, downstream application, and consumption area of Ketamine Treatment. The report also introduces players in the industry from the perspective of the value chain and looks into the leading companies.
Key Points this Global Ketamine Treatment Market Report Include:
Market Size Estimates: Ketamine Treatment market size estimation in terms of revenue and sales from 2018-2028
Market Dynamic and Trends: Ketamine Treatment market drivers, restraints, opportunities, and challenges
Macro-economy and Regional Conflict: Influence of global inflation and Russia & Ukraine War on the Ketamine Treatment market
Segment Market Analysis: Ketamine Treatment market revenue and sales by type and by application from 2018-2028
Regional Market Analysis: Ketamine Treatment market situations and prospects in major and top regions and countries
Ketamine Treatment Market
Competitive Landscape
and Major Players: Analysis of 10-15 leading market players, sales, price, revenue, gross, gross margin, product/service profile and recent development/updates, etc.Ketamine Treatment Industry Chain: Ketamine Treatment market raw materials & suppliers, manufacturing process, distributors by region, downstream customers
Ketamine Treatment Industry News, Policies by regions
Ketamine Treatment Industry Porters Five Forces Analysis
Key players in the global Ketamine Treatment market are covered in Chapter 2:
Field Trip Health
Mindbloom
Nue Life Health
Save Minds
Nushama
Numinus Wellness
Ember Health
Interpersonal Psychiatry
Klarisana
Journey Clinical
Better U
In Chapter 6 and Chapter 9, on the basis of types, the Ketamine Treatment market from 2018 to 2028 is primarily split into:
Infusions
Nasal Spray
Tablets
In Chapter 7 and Chapter 10, on the basis of applications, the Ketamine Treatment market from 2018 to 2028 covers:
Depression
Anesthesia
Pain
Other
Geographically, the detailed analysis of consumption, revenue, market share and growth rate of the following regions from 2018 to 2028 are covered in Chapter 8 and Chapter 11:
United States
Europe
China
Japan
India
Southeast Asia
Latin America
Middle East and Africa
Others
In summary, this report relies on sources from both primary and secondary, combines comprehensive quantitative analysis with detailed qualitative analysis, and pictures the market from a macro overview to micro granular segment aspects. Whatever your role in this industry value chain is, you should benefit from this report with no doubt.
Chapter Outline
This report consists of 12 chapters. Below is a brief guideline to help you quickly grasp the main contents of each chapter:
Chapter 1 first introduces the product overview, market scope, product classification, application, and regional division, and then summarizes the global Ketamine Treatment market size in terms of revenue, sales volume, and average price.
Chapter 2 analyzes the main companies in the Ketamine Treatment industry, including their main businesses, products/services, sales, prices, revenue, gross profit margin, and the latest developments/updates.
Chapter 3 is an analysis of the competitive environment of Ketamine Treatment market participants. This mainly includes the revenue, sales, market share, and average price of the top players, along with the market concentration ratio in 2022 and the players' M&A and expansion in recent years.
Chapter 4 is an analysis of the Ketamine Treatment industrial chain, including raw material analysis, manufacturing cost structure, distributors, and major downstream buyers.
Chapter 5 focuses on Ketamine Treatment market dynamics and marketing strategy analysis, which include opportunities, challenges, industry development trends under inflation, industry news and policies analyzed by region, Porter's Five Forces analysis, as well as direct and indirect marketing, and the development trends of marketing channels.
Chapters 6-8 have segmented the Ketamine Treatment market by type, application, and region, with a focus on sales and value from 2018 to 2023 from both vertical and horizontal perspectives.
Chapters 9-11 provide detailed Ketamine Treatment market forecast data for 2023-2028, broken down by type and application, region, and major countries to help understand future growth trends.
Chapter 12 concludes with an explanation of the data sources and research methods. Verify and analyze through preliminary research to obtain final quantitative and qualitative data.
Years considered for this report:
Historical Years:
2018-2022Base Year:
2022Estimated Year:
2023Forecast Period:
2023-2028Frequently Asked Questions
This market study covers the global and regional market with an in-depth analysis of the overall growth prospects in the market. Furthermore, it sheds light on the comprehensive competitive landscape of the global market. The report further offers a dashboard overview of leading companies encompassing their successful marketing strategies, market contribution, recent developments in both historic and present contexts.
- By product type
- By End User/Applications
- By Technology
- By Region
The report provides a detailed evaluation of the market by highlighting information on different aspects which include drivers, restraints, opportunities, and threats. This information can help stakeholders to make appropriate decisions before investing.
